
CLAIMS

1. Use of a p75 receptor antagonist in the preparation of medicament for use in the treatment and/or prevention of overactive bladder.

~~2. Use according to claim 1,~~ wherein said p75 receptor antagonist is a compound of general formula (I):




(I)

in which:

- $m^{(I)}$ represents 0 or 1;

- $A^{(I)}$ represents:



and $B^{(I)}$ represents a hydrogen atom

Or

$A^{(I)}$ represents a hydrogen atom and $B^{(I)}$ represents:

~~3~~2. Use according to claim 1 ~~or 2~~, wherein said p75 receptor antagonist is:

- compound n°1: 1-[4-(4-chloro-3-trifluoromethyl-phenyl)-3,6-dihydro-2H-pyridin-1-yl]-2-[8-(5-fluoro-pyrimidin-2-yl)-3,8-diaza-bicyclo[3.2.1]oct-3-yl]-ethanone ;

in the form of a base or of an addition salt with an acid.